Marathon Capital Management Abb Vie Inc. Transaction History

Marathon Capital Management

$380 Million
Q2 2024

A detailed history of Marathon Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Marathon Capital Management holds 6,422 shares of ABBV stock, worth $1.22 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

6,422

Previous 6,217 3.3%

Holding current value

$1.22 Million

Previous $1.13 Million 2.74%

% of portfolio

0.29%

Previous 0.28%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $31,731 - $37,055	205 Added 3.3%	6,422 $1.1 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $7,991 - $9,105	-50 Reduced 0.8%	6,217 $1.13 Million
Q4 2023 Feb 08, 2024	SELL	$137.6 - $154.97 $30,960 - $34,868	-225 Reduced 3.47%	6,267 $971,000
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $20,038 - $23,197	-150 Reduced 2.26%	6,492 $967,000
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $9,010 - $11,213	-68 Reduced 1.01%	6,642 $894,000
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $3.26 Million - $3.76 Million	-22,555 Reduced 77.07%	6,710 $1.07 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $21,299 - $25,543	-154 Reduced 0.52%	29,265 $4.73 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $23,755 - $27,245	-177 Reduced 0.6%	29,419 $3.95 Million
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $16,652 - $21,170	121 Added 0.41%	29,596 $4.53 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $31,939 - $39,627	-242 Reduced 0.81%	29,475 $4.78 Million
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $21,271 - $26,914	-198 Reduced 0.66%	29,717 $4.02 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $5,320 - $6,039	50 Added 0.17%	29,915 $3.23 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $13,151 - $14,651	-125 Reduced 0.42%	29,865 $3.36 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $136,059 - $149,784	1,330 Added 4.64%	29,990 $3.25 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $106,649 - $143,987	1,325 Added 4.85%	28,660 $3.07 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $83,848 - $98,410	-976 Reduced 3.45%	27,335 $2.39 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $86,209 - $115,361	1,175 Added 4.33%	28,311 $2.78 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $66,757 - $101,212	1,035 Added 3.97%	27,136 $2.07 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $1.24 Million - $1.55 Million	17,185 Added 192.74%	26,101 $2.31 Million
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $561,529 - $675,119	8,916 New	8,916 $675,000
Q2 2019 Jul 25, 2019	SELL	$65.7 - $83.98 $165,301 - $211,293	-2,516 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$77.85 - $96.01 $12,066 - $14,881	155 Added 6.57%	2,516 $231,000
Q1 2018 May 07, 2018	SELL	$92.01 - $123.21 $13,801 - $18,481	-150 Reduced 5.97%	2,361 $223,000
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $175,393 - $224,031	2,511	2,511 $223,000

Others Institutions Holding ABBV

# of Institutions

3,757

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.84M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $335B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Marathon Capital Management with notifications on news.

Account

Marathon Capital Management Abb Vie Inc. Transaction History